Blood and Urine Metabolic Biomarkers Monitor Short-term Dietary Changes
|
By LabMedica International staff writers Posted on 04 Nov 2019 |

Image: Researchers have identified several chemical signatures, detectable in blood and urine, that can accurately measure dietary intake (Photo courtesy of Medical Xpress).
Metabolites found in plasma and urine samples may serve as responsive biomarkers reflecting short-term changes in the habitual diet.
Unhealthy eating patterns have been linked to the increase in obesity and related chronic diseases such as diabetes worldwide. However, existing methods of assessing dietary intake in nutritional epidemiology rely on food frequency questionnaires or dietary records that are prone to bias and selective reporting.
To improve this situation, investigators at McMaster University (Hamilton, ON, Canada) sought to identify metabolites in readily accessible blood or urine samples that would reflect short-term changes in dietary intake. Measurement of those markers would be used to compare the foods provided to study participants to what they reported they had eaten.
Over the course of this study, metabolic phenotyping was performed on 42 healthy participants from the Diet and Gene Intervention (DIGEST) pilot study, a parallel two-arm randomized clinical trial that provided complete diets to all participants. Matching single-spot urine and fasting plasma specimens were collected at baseline, and then following two weeks of either a Prudent or Western diet with a weight-maintaining menu plan designed by a dietician. The Prudent diet was rich in fruits, vegetables, lean meats, and whole grains. The Western diet was rich in trans fats, processed foods, red meat, and sweetened beverages. Targeted and nontargeted metabolite profiling was conducted for two weeks using three complementary analytical platforms.
A modest reduction in systolic and diastolic blood pressure, and total cholesterol was reported for participants following the Prudent diet after two weeks as compared to the Western diet; however, dietary adherence relied on participant self-reporting, and food preparation methods were not standardized.
Overall, 3-methylhistidine and proline betaine concentrations increased in both plasma and urine samples after participants were assigned a Prudent diet with a corresponding decrease in the Western diet group. Similarly, creatinine-normalized urinary imidazole propionate, hydroxypipecolic acid, dihydroxybenzoic acid, and enterolactone glucuronide, as well as plasma ketoleucine and ketovaline increased with a Prudent diet after adjustments for age, sex, and BMI. In contrast, plasma myristic acid, linoelaidic acid, linoleic acid, alpha-linoleic acid, pentadecanoic acid, alanine, proline, carnitine, and deoxycarnitine, as well as urinary acesulfame K increased among participants following a Western diet. Most metabolites were also correlated to changes in the average intake of specific nutrients from self-reported diet records reflecting good adherence to assigned food provisions.
"We were able to detect short-term changes in dietary patterns which could be measured objectively," said senior author Dr. Philip Britz-McKibbin, professor of chemistry and chemical biology at McMaster University. "And it did not take long for these significant changes to become apparent. This has been a major issue in nutritional research and may be one of the main reasons for the lack of real progress in nutritional sciences and chronic disease prevention."
The dietary biomarker study was published in the October 9, 2019, online edition of the journal Nutrients.
Related Links:
McMaster University
Unhealthy eating patterns have been linked to the increase in obesity and related chronic diseases such as diabetes worldwide. However, existing methods of assessing dietary intake in nutritional epidemiology rely on food frequency questionnaires or dietary records that are prone to bias and selective reporting.
To improve this situation, investigators at McMaster University (Hamilton, ON, Canada) sought to identify metabolites in readily accessible blood or urine samples that would reflect short-term changes in dietary intake. Measurement of those markers would be used to compare the foods provided to study participants to what they reported they had eaten.
Over the course of this study, metabolic phenotyping was performed on 42 healthy participants from the Diet and Gene Intervention (DIGEST) pilot study, a parallel two-arm randomized clinical trial that provided complete diets to all participants. Matching single-spot urine and fasting plasma specimens were collected at baseline, and then following two weeks of either a Prudent or Western diet with a weight-maintaining menu plan designed by a dietician. The Prudent diet was rich in fruits, vegetables, lean meats, and whole grains. The Western diet was rich in trans fats, processed foods, red meat, and sweetened beverages. Targeted and nontargeted metabolite profiling was conducted for two weeks using three complementary analytical platforms.
A modest reduction in systolic and diastolic blood pressure, and total cholesterol was reported for participants following the Prudent diet after two weeks as compared to the Western diet; however, dietary adherence relied on participant self-reporting, and food preparation methods were not standardized.
Overall, 3-methylhistidine and proline betaine concentrations increased in both plasma and urine samples after participants were assigned a Prudent diet with a corresponding decrease in the Western diet group. Similarly, creatinine-normalized urinary imidazole propionate, hydroxypipecolic acid, dihydroxybenzoic acid, and enterolactone glucuronide, as well as plasma ketoleucine and ketovaline increased with a Prudent diet after adjustments for age, sex, and BMI. In contrast, plasma myristic acid, linoelaidic acid, linoleic acid, alpha-linoleic acid, pentadecanoic acid, alanine, proline, carnitine, and deoxycarnitine, as well as urinary acesulfame K increased among participants following a Western diet. Most metabolites were also correlated to changes in the average intake of specific nutrients from self-reported diet records reflecting good adherence to assigned food provisions.
"We were able to detect short-term changes in dietary patterns which could be measured objectively," said senior author Dr. Philip Britz-McKibbin, professor of chemistry and chemical biology at McMaster University. "And it did not take long for these significant changes to become apparent. This has been a major issue in nutritional research and may be one of the main reasons for the lack of real progress in nutritional sciences and chronic disease prevention."
The dietary biomarker study was published in the October 9, 2019, online edition of the journal Nutrients.
Related Links:
McMaster University
Latest Molecular Diagnostics News
- Machine Learning Tool Improves Prediction of Liver Cancer Recurrence
- AI-Powered Liquid Biopsy Detects Liver Cancer Across Diverse Populations
- Circular RNAs Enable Noninvasive Cancer Detection and Risk Assessment
- Polygenic Risk Score Test Estimates Inherited Coronary Artery Disease Risk
- AI Tool Improves Long-Read Detection of Cancer Mutations
- FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
- Blood Gene Expression Fluctuates More Than Expected Over Time
- Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer
- Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
- Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
- Portable Rapid Test Aims to Detect Ebola at Point of Care
- New Test Delivers Four Prenatal Genetic Screens from One Blood Sample
- Point-of-Care Molecular Technology Promises Transformative Shift in Oncology
- Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
- Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
- New Biomarker Helps Guide Combination Therapy for Treatment-Resistant Breast Cancer
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Portable Molecular Platform to Advance Point-of-Care Testing for Lassa Fever
Lassa fever remains a persistent public health threat in West Africa, causing an estimated 100,000–300,000 infections annually and high case fatality rates among hospitalized patients. Clinical management... Read more
Study Highlights Need for Routine Hepatitis E Testing in Cirrhosis
Hepatitis E virus is a leading cause of acute viral hepatitis globally, yet infections often go unnoticed in healthy individuals. For patients with preexisting liver damage, however, infection can trigger... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel







